All In Biotech

Drug Trial Radar · NCT06577025

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

43

Actual

Start

Aug 20, 2024

Primary completion

Sep 2, 2030

Study completion Sep 30, 2030

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.

Conditions

  • Multiple Myeloma

Interventions

  • Cilta-celDrug

    Cilta-cel infusion will be administered intravenously.

  • TalquetamabDrug

    Talquetamab will be administered subcutaneously.

  • DaratumumabDrug

    Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.

  • TeclistamabDrug

    Teclistamab will be administered subcutaneously.

  • BortezomibDrug

    Bortezomib will be administered subcutaneously as a part of induction.

  • LenalidomideDrug

    Lenalidomide will be administered orally as a part of induction.

  • DexamethasoneDrug

    Dexamethasone will be administered orally as a part of induction.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered intravenously as a part of conditioning regimen.

  • FludarabineDrug

    Fludarabine will be administered intravenously as a part of conditioning regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Response with Curative PotentialTime frame: Up to 5 years
  2. Progression Free Survival (PFS) Rate at 3-YearTime frame: At 3-year
  3. PFS Rate at 5-YearTime frame: At 5-year

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of California San Francisco

    San Francisco, California

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Peter MacCallum Cancer Centre

    Melbourne, Australia

  • The Alfred Hospital

    Melbourne, Australia

  • IDOR - Regional Bahia

    Salvador, Brazil

  • Fundacao Antonio Prudente A C Camargo Cancer Center

    São Paulo, Brazil

  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

    São Paulo, Brazil

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany

  • Universitaetsklinikum Tuebingen

    Tübingen, Germany

  • Universitatsklinikum Wurzburg

    Würzburg, Germany

  • Hosp. Univ. 12 de Octubre

    Madrid, Spain

  • Hosp Clinico Univ de Salamanca

    Salamanca, Spain

  • Hosp. Univ. Marques de Valdecilla

    Santander, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.